STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Stat News • 5/22/2026
Summary
Retro Biosciences, a longevity startup backed by OpenAI CEO Sam Altman, has announced that it has raised additional funding, resulting in a valuation of $1.8 billion. This announcement was made on Friday.
Advertisement
Lindy Score Breakdown (V4.2)
5h
Age
1
Sources
from cluster
3
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier96% (0.5^3/48)
Hero EligibleYes
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about biotech investors’ mood, a former FDA head’s confidence, and more
Stat News • 2 days ago
STAT+: RFK Jr.’s screen time warning
Stat News • 1 day ago
STAT+: Immunovant shares surge on arthritis trial data
Stat News • 1 day ago
STAT+: EU and US advisers split over AstraZeneca breast cancer drug
Stat News • Today
STAT+: Closely watched experimental Parkinson’s drug fails key clinical trial
Stat News • Today
STAT+: Pharmalittle: We’re reading about a Lilly obesity drug trial, statistics for an Alzheimer’s drug, and more
Stat News • 1 day ago
STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
Stat News • Today
Guarding biotech from China and big bets in longevity
Stat News • 1 day ago
STAT+: Elevance executive ordered to testify in Medicare Advantage fraud case
Stat News • 1 day ago
